{"entity":{"id":"nct06445400","kind":"trial","name":"A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive ","aka":[],"tldr":"A phase 2 trial of Trastuzumab brengitecan, Pertuzumab, Docetaxel in her2-positive breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.","summary":"A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer is a phase 2 interventional study registered as NCT06445400 by Sichuan Baili Pharmaceutical Co., Ltd., with 83 participants enrolled, started 2024-06-19 and due to reach its primary completion in 2025-07-21. Interventions recorded: BL-M07D1, Pertuzumab, Docetaxel. Conditions listed: HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06445400","url":"https://clinicaltrials.gov/study/NCT06445400"}],"tags":["ctgov-ingest"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab-brengitecan","pertuzumab","docetaxel"],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06445400","phase":"2","setting":"A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel as First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","enrolled":83,"outcomes":[]},"route":"/trials/nct06445400/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"},{"id":"trastuzumab-brengitecan","kind":"drug","name":"Trastuzumab brengitecan","route":"/drugs/trastuzumab-brengitecan/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}]}}